Research Efforts Underway to Target CEACAM5 in NSCLC

Clinicians tasked with treating patients with non–small cell lung cancer may soon be gaining an additional therapeutic target, this one directed at CEACAM5.

Tusamitamab ravtansine, an antibody-drug conjugate that targets CEACAM5, could expand the treatment armamentarium for patients with CEACAM5-positive nonsquamous non–small cell lung cancer.

Alexander Spira, MD, PhD, FACP, discusses the rationale for targeting CEACAM5 in NSCLC, how tusamitamab ravtansine could provide encouraging frontline responses in the CEACAM5-positive, nonsquamous population, and enrollment challenges faced by ongoing clinical trials.